US2020384091A1PendingUtilityA1

Method of treating depression

72
Assignee: FINZI ERICPriority: Feb 7, 2003Filed: Aug 24, 2020Published: Dec 10, 2020
Est. expiryFeb 7, 2023(expired)· nominal 20-yr term from priority
Inventors:Eric Finzi
A61K 38/4893A61K 9/0019A61K 45/06C12Y 304/24069A61K 31/135A61K 31/4525A61P 25/24A61K 45/00A61K 31/137A61P 25/22A61K 39/08
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis , orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.

Claims

exact text as granted — not AI-modified
1 . A method for treating an affective disorder in a subject, comprising:
 administering a therapeutically effective amount of a composition comprising a  botulinum  toxin to one or more facial muscle involved in frowning, scowling or a sad appearance; wherein the therapeutically effective amount is an amount sufficient to cause paralysis of the one or more facial muscle;   thereby treating the affective disorder in the subject.   
     
     
         2 . The method of  claim 1 , wherein the one or more facial muscle involved in frowning, scowling or a sad appearance is selected from the group consisting of  frontalis , orbicularis oculi, procerus, corrugator supercilii, and depressor anguli oris muscle. 
     
     
         3 . The method of  claim 1 , wherein the one or more facial muscle is a  frontalis  muscle, an orbicularis oculi muscle, or a procerus muscle. 
     
     
         4 . The method of  claim 1 , wherein the one or more facial muscle is a corrugator supercilii muscle, or a procerus muscle. 
     
     
         5 . The method of  claim 1 , wherein the  botulinum  toxin in the composition is selected from the group consisting of the  botulinum  toxins types A, B, C 1 , D, E, F and G. 
     
     
         6 . The method of  claim 5 , wherein the  botulinum  toxin in the composition is  botulinum  toxin A. 
     
     
         7 . The method of  claim 1 , wherein the therapeutically effective amount is about 5-60 Unit equivalents of a  botulinum  toxin type A. 
     
     
         8 . The method of  claim 7 , further comprising administering a second composition comprising an additional therapeutically effective amount of the  botulinum  toxin type A to the one or more facial muscle after about two to six months. 
     
     
         9 . The method of  claim 1 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression. 
     
     
         10 . The method of  claim 9 , wherein the additional modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression. 
     
     
         11 . The method of  claim 9 , wherein the additional modality of treatment comprises a selective serotonin reuptake inhibitor.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.